Skip to main content

Advertisement

SpringerLink
Log in

Update on the Use of Zoledronic Acid in the Management of Osteoporosis

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Zoledronic acid is a third-generation bisphosphonate that is administered as an annual infusion, and it has some interesting features. After a successful preclinical development program, it has undergone extensive testing in postmenopausal osteoporosis where it has substantial antifracture efficacy at the vertebral, nonvertebral, and hip sites. It has been shown to be effective in reducing vertebral and nonvertebral fractures in patients who had recently suffered a femoral neck fracture, and has demonstrated efficacy in preventing and reversing bone loss in glucocorticoid osteoporosis. The drug is generally well tolerated, although it has been shown to cause significant acute phase reactions occurring in the first 3 days, mainly after the first infusion. Care must be taken to avoid using the drug in those with significantly impaired renal function, although initial concerns about a relationship to atrial fibrillation and osteonecrosis of the jaw have so far proved to be unfounded.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Reid IR, Miller P, Lyles K, et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005, 353:898-908.

    Article  CAS  PubMed  Google Scholar 

  2. Hosking D, Lyles K, Brown JP, et al.: Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007, 22:142–148.

    Article  CAS  PubMed  Google Scholar 

  3. Russell RG, Xia Z, Dunford JE, et al.: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209–257.

    Article  CAS  PubMed  Google Scholar 

  4. Delmas PD, Adami S, Strugala C, et al.: Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006, 54:1838–1846.

    Article  CAS  PubMed  Google Scholar 

  5. Eisman JA, Civitelli R, Adami S, et al.: Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008, 35:488–497.

    CAS  PubMed  Google Scholar 

  6. Harris ST, Blumentals WA, Miller PD: Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008, 24:237–245.

    Article  CAS  PubMed  Google Scholar 

  7. Hornby SB, Evans GP, Hornby SL, et al.: Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 2003, 72:519–527.

    Article  CAS  PubMed  Google Scholar 

  8. Glatt M, Pataki A, Evans GP, et al.: Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 2004, 15:707–715.

    Article  CAS  PubMed  Google Scholar 

  9. Gasser JA, Ingold P, Venturiere A, et al.: Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008, 23:544–551.

    Article  CAS  PubMed  Google Scholar 

  10. Brouwers JE, Ruchelsman M, Rietbergen B, Bouxsein ML: Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats. Osteoporos Int 2009, 20:1377–1384.

    Article  CAS  PubMed  Google Scholar 

  11. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.

    Article  CAS  PubMed  Google Scholar 

  12. •• Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809–1822. The study reported on the pivotal phase 3, placebo-controlled, randomized antifracture trial showing the significant benefit of ZOL in the prevention of fractures in postmenopausal women. The study showed a good safety profile but indicted the significant increase in acute phase reactions and also showed a significant increase in AF reported as serious adverse events.

  13. Eastell R, Lang T, Boonen S, et al.: Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2009 Oct 3 [Epub ahead of print].

  14. Cummings SR, Schwartz AV, Black DM: Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895–1896.

    Article  CAS  PubMed  Google Scholar 

  15. Heckbert SR, Li G, Cummings SR, et al.: Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826–831.

    Article  CAS  PubMed  Google Scholar 

  16. Sorensen HT, Christensen S, Mehnert F, et al.: Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population-based case-control study. BMJ 2008, 336:813–816.

    Article  PubMed  Google Scholar 

  17. Grosso A, Douglas I, Hingorani A, et al.: Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009, 4:e4720.

    Article  PubMed  Google Scholar 

  18. Bunch TJ, Anderson JL, May HT, et al.: Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009, 103:824–828.

    Article  CAS  PubMed  Google Scholar 

  19. Abrahamsen B, Eiken P, Brixen K: Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581–592.

    Article  CAS  PubMed  Google Scholar 

  20. Loke YK, Jeevanantham V, Singh S: Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009, 32:219–228.

    Article  CAS  PubMed  Google Scholar 

  21. •• Lyles KW, Colon-Emeric CS, Magaziner JS, et al.: Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1799–1809. The is the second major phase 3, placebo-controlled, randomized trial demonstrating efficacy of ZOL in fracture prevention in men and women who had recently sustained a femoral neck fracture. The trial demonstrated reduced mortality in the ZOL group compared with placebo.

  22. Boonen S, Black DM, Colon-Emeric CS, et al.: Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis Aged 75 and Older. J Am Geriatr Soc 2010, 58:292–299.

    Article  PubMed  Google Scholar 

  23. Eriksen EF, Lyles KW, Colon-Emeric CS, et al.: Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009, 24:1308–1313.

    Article  CAS  PubMed  Google Scholar 

  24. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al.: Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010, 25:91–97.

    CAS  PubMed  Google Scholar 

  25. Cummings SR, San Martin J, McClung MR, et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756–765.

    Article  CAS  PubMed  Google Scholar 

  26. Recker RR, Kendler D, Recknor CP, et al.: Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007, 40:843–851.

    Article  CAS  PubMed  Google Scholar 

  27. Reid DM, Hosking D, Kendler D, et al.: A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 2008, 62:575–584.

    Google Scholar 

  28. Luckey M, Kagan R, Greenspan S, et al.: Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004, 11:405–415.

    Article  PubMed  Google Scholar 

  29. Saag K, Lindsay R, Kriegman A, et al.: A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007, 40:1238–1243.

    Article  CAS  PubMed  Google Scholar 

  30. McClung M, Recker R, Miller P, et al.: Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122–128.

    Article  CAS  PubMed  Google Scholar 

  31. •• Reid DM, Devogelaer JP, Saag K, et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253–1263. This is the third RCT demonstrating superiority of an annual infusion of ZOL compared with daily oral RIS in the prevention and treatment of glucocorticoid-induced osteoporosis. Fractures were very rare in the 1-year trial, but there was no difference between the treatments used.

    Article  CAS  PubMed  Google Scholar 

  32. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.

    Article  CAS  PubMed  Google Scholar 

  33. Bhoopalam N, Campbell SC, Moritz T, et al.: Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009, 182:2257–2264.

    Article  CAS  PubMed  Google Scholar 

  34. Ryan CW, Huo D, Bylow K, et al.: Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007, 100:70–75.

    Article  CAS  PubMed  Google Scholar 

  35. Poole KE, Loveridge N, Rose CM, et al.: A single infusion of zoledronate prevents bone loss after stroke. Stroke 2007, 38:1519–1525.

    Article  CAS  PubMed  Google Scholar 

  36. Bolland MJ, Grey AB, Horne AM, et al.: Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007, 92:1283–1288.

    Article  CAS  PubMed  Google Scholar 

  37. xGnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:8200–828.

    Article  Google Scholar 

  38. Hines SL, Sloan JA, Atherton PJ, et al.: Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast 2010, 19:92–96.

    Article  PubMed  Google Scholar 

  39. Hershman DL, McMahon DJ, Crew KD, et al.: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739–4745.

    Article  CAS  PubMed  Google Scholar 

  40. Chapman I, Greville H, Ebeling PR, et al.: Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol (Oxf) 2009, 70:838–846.

    Article  CAS  Google Scholar 

  41. Bubbear JS, Gall A, Middleton FR, et al.: Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int 2010 Apr 1 [Epub ahead of print].

  42. Adami S, Zamberlan N: Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996, 14:158–170.

    Article  CAS  PubMed  Google Scholar 

  43. Thiebaud D, Sauty A, Burckhardt P, et al.: An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997, 61:386-392.

    Article  CAS  PubMed  Google Scholar 

  44. Kunzmann V, Bauer E, Wilhelm M: Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999, 340:737–738.

    Article  CAS  PubMed  Google Scholar 

  45. Thompson K, Rogers MJ: Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19:278–288.

    Article  CAS  PubMed  Google Scholar 

  46. Srivastava T, Haney CJ, Alon US: Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 2009, 24:334–337.

    Article  PubMed  Google Scholar 

  47. Reid IR: Osteonecrosis of the jaw: who gets it, and why? Bone 2009, 44:4–10.

    Article  CAS  PubMed  Google Scholar 

  48. Grbic JT, Landesberg R, Lin SQ, et al.: Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008, 139:32–40.

    CAS  PubMed  Google Scholar 

  49. Colucci A, Modorati G, Miserocchi E, et al.: Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm 2009, 17:267–268.

    Article  PubMed  Google Scholar 

  50. Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51–57.

    Article  CAS  PubMed  Google Scholar 

  51. Boonen S, Sellmeyer DE, Lippuner K, et al.: Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74:641–648.

    Article  CAS  PubMed  Google Scholar 

  52. Recker RR, Delmas PD, Halse J, et al.: Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6–16.

    Article  CAS  PubMed  Google Scholar 

  53. Odvina CV, Levy S, Rao S, et al.: Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72:161–168.

    Article  CAS  Google Scholar 

  54. Lenart BA, Lorich DG, Lane JM: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304–1306.

    Article  CAS  PubMed  Google Scholar 

  55. • Black DM, Kelly MP, Genant HK, et al.: Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761–1771. This is a post hoc analysis examining the use of ZOL and alendronate in postmenopausal osteoporosis demonstrating no increased risk of atypical femoral fractures over a 3- to 10-year period of use, with the later time frame being with alendronate only.

  56. • McClung M, Miller P, Recknor C, et al.: Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009, 114:999–1007. This is a trial demonstrating that ZOL can reverse bone loss in postmenopausal women with low bone mass but not necessarily osteoporosis. The trial showed near equal efficacy of annual and biannual infusions of the drug.

  57. Grey A, Bolland MJ, Wattie D, et al.: The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009, 94:538–544.

    Article  CAS  PubMed  Google Scholar 

  58. Bolland MJ, Grey AB, Horne AM, et al.: Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res 2008, 23:1304–1308.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Prof. David M. Reid is a member of the International Bone Scientific Advisory Board, is on the speakers’ bureau, and has received research grant funding for company-sponsored and investigator-initiated studies.

Author information

Authors and Affiliations

  1. Head of Division of Applied Medicine & Professor of Rheumatology, School of Medicine & Dentistry, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK

    David M. Reid

Authors
  1. David M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Reid.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, D.M. Update on the Use of Zoledronic Acid in the Management of Osteoporosis. Curr Osteoporos Rep 8, 145–150 (2010). https://doi.org/10.1007/s11914-010-0021-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-010-0021-4

Keywords

Search

Navigation